Icon of the Instituts for Quality and Efficiency in Health Care

[A24-87] Durvalumab (endometrial cancer) – Benefit assessment according to §35a Social Code Book V

Last updated 02.12.2024

Project no.:
A24-87

Commission:
Commission awarded on 22.08.2024 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Topic:
Cancer

Indication:

First-line treatment of adult patients with primary advanced or recurrent mismatch repair deficient endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with durvalumab

Result of dossier assessment:

Added benefit not proven

Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

DOI:

https://doi.org/10.60584/A24-87_en

Project no. Title Status
A23-138 Durvalumab (HCC) – Benefit assessment according to §35a Social Code Book V Commission completed
A23-27 Durvalumab (hepatocellular carcinoma [HCC]) – Benefit assessment according to §35a Social Code Book V Commission completed
A23-30 Tremelimumab (hepatocellular carcinoma [HCC]) – Benefit assessment according to §35a Social Code Book V Commission completed
A23-29 Tremelimumab (NSCLC) – Benefit assessment according to §35a Social Code Book V Commission completed
A23-31 Durvalumab (NSCLC) – Benefit assessment according to §35a Social Code Book V Commission completed
A20-87 Durvalumab (small cell lung cancer) - Benefit assessment according to §35a Social Code Book V Commission completed
A18-69 Durvalumab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V Commission completed
A24-86 Durvalumab (first-line in combination with carboplatin and paclitaxel, maintenance in combination with olaparib; endometrial cancer) – Benefit assessment according to §35a Social Code Book V Commission completed

Contact

Press contact

+49 221 356850

presse@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form

Print page